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Abstract 1 
Purpose: To investigate longitudinal changes of subbasal nerve plexus (SNP) morphology 2 
and its relationship with conventional measures of neuropathy in individuals with diabetes.  3 
Methods: A cohort of 147 individuals with type 1 diabetes and 60 age-balanced controls 4 
underwent detailed assessment of clinical and metabolic factors, neurologic deficits, 5 
quantitative sensory testing, nerve conduction studies and corneal confocal microscopy at 6 
baseline and four subsequent annual visits. The SNP parameters included corneal nerve 7 
fiber density (CNFD), branch density (CNBD) and fiber length (CNFL) and were quantified 8 
using a fully-automated algorithm. Linear mixed models were fitted to examine the changes 9 
in corneal nerve parameters over time. 10 
Results: At baseline, 27% of the participants had mild diabetic neuropathy. All SNP 11 
parameters were significantly lower in the neuropathy group compared to controls (P<0.05). 12 
Overall, 89% of participants examined at baseline also completed the final visit. There was 13 
no clinically significant change to health and metabolic parameters and neuropathy 14 
measures from baseline to the final visit. Linear mixed model revealed a significant linear 15 
decline of CNFD (annual change rate, -0.9 nerve/mm2, P=0.01) in the neuropathy group 16 
compared to controls, which was associated with age (β=-0.06, P=0.04) and duration of 17 
diabetes (β=-0.08, P=0.03). In the neuropathy group, absolute changes of CNBD and CNFL 18 
showed moderate correlations with peroneal conduction velocity and cold sensation 19 
threshold, respectively (rs, 0.38 and 0.40, P<0.05).  20 
Conclusion: This study demonstrates dynamic small fiber damage at the SNP, thus providing 21 
justification for our ongoing efforts to establish corneal nerve morphology as an appropriate 22 
adjunct to conventional measures of DPN.  23 
  24 
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Introduction 1 
Diabetic neuropathy is a substantial and burdensome complication of diabetes, affecting up 2 
to 50% of these individuals.1 Diabetic peripheral neuropathy (DPN), which is the most 3 
common form of neuropathy, manifests as a distal, symmetric polyneuropathy that begins 4 
in the lower extremities and may progress proximally.2 DPN leads to morbidity in diabetic 5 
patients in the form of painful neuropathy and foot ulceration with consequent lower limb 6 
amputation.3 It accounts for reduced quality of life and imposes a significant economic 7 
burden that affects both individuals and society.4, 5 8 
Several established tests are commonly used for screening, detection and assessment of 9 
DPN and to monitor its progression. The majority of these tests examine neuronal function; 10 
however, direct observation of nerve structure is also possible. Neurologic symptoms and 11 
signs, quantitative sensory tests (QST) and nerve conduction studies (NCS) are the most 12 
commonly used tests for DPN.6 Indeed symptoms, neurological deficits and NCS constitute 13 
the basis on which diabetic neuropathy is diagnosed. QST provide quantitative measures of 14 
sensation; however, these tests require cooperation and concentration of the examinee and 15 
they may also be affected by anthropometric variables.7 Whilst recent studies have shown 16 
that the proficiency of QST assessment is adequate,8 the reproducibility of symptoms and 17 
signs9 and NCS10 has been shown to be limited. Furthermore studies in patients with 18 
impaired glucose tolerance (IGT)11 and recently diagnosed type 2 diabetes12 show a marked 19 
small fiber neuropathy accompanying large fiber dysfunction.  20 
Quantification of nerve pathology is possible through direct morphometric examination of 21 
nerves including sural nerve biopsy13 and skin biopsy.14 However, these techniques are 22 
invasive, require expertise for quantification and cannot be repeated from the same site for 23 
longitudinal studies. Accurate detection and estimation of progression are needed, 24 
especially to test putative treatments, which may alleviate the condition, and/or prevent or 25 
delay the development of sequelae. As reviewed in more detail elsewhere,15, 16 based on the 26 
pathogenesis of DPN, several potential therapeutic approaches have been developed 27 
targeting these mechanisms; however, apart from glucose control and pain management, 28 
currently there is no approved treatment for DPN.15, 17  29 
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Lack of a sensitive, accurate and reliable clinical endpoint has been one of the obstacles in 1 
mounting treatment trials for DPN.18 Growing evidence supports a prominent association 2 
between corneal subbasal nerve plexus (SNP) morphology measured with corneal confocal 3 
microscopy (CCM) and DPN. CCM as a quick, non-invasive and reiterative technique has a 4 
demonstrated capacity to detect early small nerve fiber damage in diabetic patients,19 and 5 
diagnose20-22 and classify severity of DPN.23, 24 Conventional measures of neuropathy and 6 
corneal nerve parameters are also related.21, 23, 25 Furthermore, the demonstration of early 7 
corneal nerve regeneration following simultaneous pancreas and kidney transplantation26 8 
and optimised glycemic and lipid control in an observational study27 suggests that CCM may 9 
well fulfil some of the criteria for a surrogate end point for diabetic neuropathy. 10 
To our knowledge, no study has been conducted to date concerning the natural course of 11 
the SNP structure over time in diabetic patients. Therefore in this study, we sought to 12 
investigate the natural history of the SNP morphology in type 1 diabetic individuals without 13 
and with mild neuropathy. Furthermore, the longitudinal relationship between changes in 14 
corneal nerve structure and established measures of neuropathy in individuals with 15 
diabetes was also addressed. 16 
Methods 17 
Study Design and Participants 18 
This prospective, observational, longitudinal study was conducted following approval from 19 
Queensland University of Technology, Princess Alexandra Hospital, and Mater Hospital 20 
research ethics committees as a part of the LANDMark study28 in Brisbane, Australia. Prior 21 
to their enrolment, written informed consent was obtained from all participants and the 22 
research adhered to the tenets of the Declaration of Helsinki. Based upon the 23 
inclusion/exclusion criteria, 147 type 1 diabetic participants were recruited from Diabetes 24 
and Endocrinology Research Centre at Princess Alexandra and Mater hospitals and the 25 
general population in Brisbane. Sixty healthy participants, without peripheral neuropathy 26 
and/or diabetes were also recruited as controls. All participants were assessed at baseline 27 
and assessments continued for four annual subsequent visits (five time-points in total and 28 
approximately 960 case visits). Participants were excluded in this study for any of the 29 
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following: history of ocular trauma or surgery, ocular disease or systemic disease with 1 
potential corneal effect, and systemic disease (other than diabetes). Other causes of 2 
neuropathy were excluded. Diabetic participants with moderate and severe neuropathy 3 
were also excluded. All participants underwent neurologic and medical evaluation as well as 4 
ocular screening (visual acuity, slit lamp examination and intraocular pressure) and CCM, 5 
which were repeated annually.  6 
For the definition of DPN, we followed accepted criteria29 that rely on the presence of 7 
abnormal electrophysiological finding, based on age-matched controls at the site, in 8 
addition to clinical signs and/or symptoms, which was defined as one or more of the 9 
followings: (i) neuropathy disability score (NDS) ≥ 3 of 10,30 or (ii) diabetic neuropathy 10 
symptom score (DNS) ≥ 1 of 4.31 The methods used during this study to assess neuropathy 11 
and clinical and metabolic factors have been reported in detail elsewhere28 and will be 12 
described only briefly here. 13 
Assessment of Neuropathy 14 
Neuropathy signs and symptoms: The neuropathy disability score (NDS), which is a scale of 0 15 
to 10, was employed to assess neurological deficits. This measure included assessment of 16 
vibration, pin-prick and temperature perception as well as presence or absence of ankle 17 
reflexes in both lower limbs. Diabetic neuropathy symptom score (DNS), a scale of 0 to 4, 18 
was used to assess symptoms of neuropathy. 19 
Quantitative sensory tests (QST): QST comprised of vibration perception, measured on the 20 
plantar surface of the big toe, and thermal (warm and cold) sensation which was assessed 21 
on the dorsal surface of the foot on the hand dominant side.   22 
Nerve conduction studies (NCS): Peroneal motor nerve conduction velocity (ankle to fibula 23 
head), amplitude (ankle to extensor digitorum brevis) and F wave latency were determined 24 
on the hand dominant side of the participants. 25 
General Health and Metabolic Assessment 26 
At each visit, all participants underwent assessment of height, weight, BMI, blood pressure, 27 
HbA1c and lipid profile.  28 
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Corneal Confocal Microscopy and Image Analysis 1 
CCM was carried out using the Rostock Cornea Module in combination with a HRT 3 2 
confocal microscope (Heidelberg Engineering, Heidelberg, Germany). Eight images of the 3 
SNP, showing in focus nerves and not overlapping more than 20%,32 were acquired from the 4 
centre of cornea on the hand-dominant side using manual focusing and section mode. 5 
Automatic segmentation and quantification of the SNP parameters including corneal nerve 6 
fiber density (CNFD), branch density (CNBD) and fiber length (CNFL) was performed using 7 
ACCMetrics,33 which is a fully automated analytical system. The SNP parameters for each 8 
participant were the average value obtained from the eight captured images and expressed 9 
in the unit of number/mm2 for CNFD and CNBD, and mm/mm2 for CNFL. 10 
Intra- and Interobserver Repeatability of the SNP Parameters 11 
In order to ascertain the repeatability of the SNP parameters from one time to another, 12 
test-retest was carried out by performing CCM examination and automated image analysis 13 
for 16 participants including 10 with diabetes and six healthy controls by a single operator as 14 
described above. Each participant was examined twice, on the same day of examination, at 15 
least 30 minutes apart. No significant differences were found between test and retest 16 
measurements for CNFD, CNBD and CNFL (P = 0.59, P = 0.88 and P = 0.94, respectively). The 17 
intraclass correlation coefficients (ICC) and coefficient of repeatability (CoR) were 0.81 and 18 
0.08 for CNFD, 0.84 and 0.20 for CNBD, and 0.90 and 0.03 for CNFL, respectively. 19 
To assess the inter-observer reproducibility of the SNP parameters, 11 participants (six with 20 
diabetes and five healthy controls) underwent CCM examinations twice by two experienced 21 
operators on the same day of examination. The differences of the SNP parameters were not 22 
statistically significant for two observers (CNFD, P = 0.29; CNBD, P = 0.22 and CNFL, P = 23 
0.21). The estimated ICC and CoR were 0.87 and 0.10 for CNFD, 0.93 and 0.23 for CNBD, and 24 
0.94 and 0.04 for CNFL, respectively. Overall, CNFL and CNFD achieved the highest values for 25 
repeatability and reproducibility, whereas CNBD showed an acceptable consistency within- 26 
and between observers.  27 
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Statistical Analysis 1 
Normality of the data was examined using the Kolmogorov-Smirnov test and the 2 
appropriate test was applied for analysis. Data are presented as mean ± standard deviation 3 
(SD) or median and interquartile range (IQR). Four sets of analyses were conducted. First, 4 
the demographic and clinical characteristics variables were compared between control and 5 
diabetic groups as well as between baseline and final visit.  Second, using Toronto criteria, 6 
participants with diabetes were stratified into those without DPN (DPN-ve) and with DPN 7 
(DPN+ve). Corneal nerve parameters and established neuropathy measures were compared 8 
between control, DPN-ve and DPN+ve. For the purpose of the two aforementioned 9 
analyses, parametric data were analyzed using the independent samples t test, paired t test, 10 
one-way ANOVA and Scheffe post hoc test (pairwise comparison). Nonparametric data were 11 
analyzed using the chi square test, Kruskal Wallis test and Mann-Whitney U test. 12 
Thirdly, a linear mixed model was employed to examine changes over time in the SNP 13 
parameters and whether the changes were different in the DPN-ve and DPN+ve groups 14 
compared with controls. Since change in the SNP parameters (i.e. CNFD, CNBD and CNFL) 15 
over time was one of the main parameters of interest of the current study, they were 16 
individually considered as response variables and time was added to the model to test the 17 
linear effect of time on the response variables. The first model contained CNFD as the 18 
response variable, group (i.e. controls, DPN-ve and DPN+ve), time and time*group 19 
interaction as primary fixed effects of interest and Type III sum of squares was selected. 20 
Group was included as a time-invariant predictor variable to explore any group differences 21 
over time.  22 
The association between the initial CNFD parameter and the change in this parameter was 23 
estimated by calculating the covariance matrix. Here, the ‘variance components’ option was 24 
chosen and also the restricted maximum likelihood estimates for parameters was used. The 25 
process of the aforementioned model was repeated for CNBD and CNFL. Depending on 26 
whether the time*group interaction was statistically significant or not, a second set of fixed 27 
effects – namely gender, age at enrolment, duration of diabetes, HbA1c, lipid profile, blood 28 
pressure, BMI, alcohol and tobacco consumption – were included and their effects were 29 
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examined. A stepwise elimination of the variables with non-statistically significant P-values 1 
was also applied. 2 
The relation between risk factors and the changes of SNP parameters in diabetic individuals, 3 
regardless of their neuropathy status, was analyzed with the latter model where all relevant 4 
risk factors were included. Control participants were excluded and group, as factor, was also 5 
removed from the model.  6 
Finally, to explore the relationship between changes in corneal nerve parameters and 7 
functional measures of neuropathy, absolute change in all parameters was calculated 8 
(∆parameter = parameter value at final visit – parameter value at baseline). Bivariate 9 
correlations between absolute change of corneal nerve parameters and neuropathy 10 
measures were estimated using Pearson r and Spearman's rho correlation coefficients, 11 
where appropriate.  12 
IBM SPSS 21 was used for all statistical tests and a two-tailed α=0.05 level of significance 13 
was considered for all analyses. 14 
Results 15 
Table 1 shows the clinical characteristics and demographic data of participants with 16 
diabetes and controls at baseline and final visit. Approximately 95% of the entering 17 
participants were Caucasians of European decent. There was no significant difference 18 
between the mean age of participants with diabetes and controls (P = 0.11). There were no 19 
statistically significant differences between diabetes and control groups with respect to 20 
HDL, triglycerides, diastolic BP, BMI and number of cigarettes smoked per day (P > 0.25). 21 
Compared to controls, individuals with diabetes had a higher HbA1c (% NGSP) (P < 0.001) 22 
and systolic BP (P = 0.03) and lower total cholesterol (P < 0.001), LDL (P < 0.001) and alcohol 23 
consumption (P = 0.001).  24 
The number of participants attending annual visits is depicted graphically in Figure 1.  25 
Altogether, 184 participants (89% of the baseline participants) completed the final visit.  26 
Personal decision was the main reason for withdrawal (13 participants) followed by poor 27 
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health (6 participants). Four participants were also lost to follow up during the study period. 1 
The median follow up duration was 3.7 years (range, 3.4 – 4.3) for the cohort.  2 
As can be seen from Table 1, at final visit HbA1c showed a clinically insignificant decrease in 3 
controls (mean difference 0.2%, P < 0.001), while it remained the same in participants with 4 
diabetes (P = 0.65). Lipid profile, blood pressure, height and alcohol consumption did not 5 
differ at final visit compared to baseline visit for both diabetes and control groups (P > 0.05).  6 
Whilst BMI showed a statistically significant increase at the final visit in participants with 7 
diabetes (P = 0.02), there was no change in controls (P = 0.42). Both control and diabetic 8 
participants reported less smoking (number of cigarette/day) at the final visit compared to 9 
baseline (P = 0.001). 10 
Comparison of the mean or median change from baseline to final visit in neuropathy 11 
measures of individuals with diabetes showed that there were no significant changes in DNS 12 
[median 0 (0 – 0) vs. 0 (0 – 0), P = 0.56], cold sensation threshold [median 28.5 (24.8 – 28.5) 13 
vs. 28.5 (26.0 vs. 28.5) °C, P = 0.85], vibration threshold [median 6.8 (2.5 – 6.8) vs. 6.6 (2.9 – 14 
6.6) Hz, P = 0.42] and peroneal F wave latency [mean 52.0 ± 5.1 vs. 52.2 ± 7.7 ms, P = 0.85]. 15 
NDS [median 1.0 (0.0 – 1.0) vs. 0.0 (0.0 – 0.0), P < 0.01], warm sensation threshold [median 16 
37.6 (34.9 – 37.6) vs. 36.6 (34.8 - 36.6) °C, P < 0.01] and peroneal amplitude [mean 4.6 ± 2.6 17 
vs. 5.0 ± 2.5 mV, P = 0.03] showed slight but significant improvements, whilst peroneal 18 
nerve conduction velocity [mean 45.3 ± 6.0 vs. 44.4 ± 5.8 m/s, P = 0.03] was the only 19 
measure that declined significantly from baseline to final visit.   20 
Using Toronto criteria, in 147 individuals with type 1 diabetes, 39 (27%) were diagnosed 21 
with DPN at baseline. Table 2 delineates the outcomes of the SNP parameters and 22 
neuropathy assessment by DPN status. SNP parameters were significantly reduced in DPN-23 
ve and DPN+ve groups compared to controls (P < 0.01). All established neuropathy 24 
measures were significantly different between groups. QST, peroneal F wave latency and 25 
peroneal amplitude displayed greater deficits in the DPN+ve group compared to DPN-ve and 26 
control groups (P < 0.05). Peroneal nerve conduction velocity was significantly lower in both 27 
DPN-ve and DPN+ve groups compared to controls and there was also a significant difference 28 
between DPN-ve and DPN+ve groups (P < 0.05). NDS and DNS were significantly higher in 29 
DPN+ve group compared to control and DPN-ve groups (P < 0.001). 30 
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Figure 2 illustrates the 4-year time course for the SNP parameters in the cohort by 1 
neuropathy status. The results of the three created basic linear mixed model (LMM) 2 
analyses for CNFD, CNBD and CNFL can be found in Table 3. The Type III tests of fixed effects 3 
shows overall test of significance for the predictors included in the three basic models (LMM 4 
1-3). There was a significant effect of group for all three models; however the effect of time 5 
was not significant for any of them. The Type III F test for the interaction between group and 6 
time was only significant in LMM1; therefore no more models were fitted for CNBD and 7 
CNFL as response variables.  8 
A second subset of fixed effects was included in LMM1. Upon sequential removal of non-9 
statistically significant fixed effects and considering the lower resultant Akaike’s information 10 
criteria (AIC) for comparing alternative models,34 a final model (LMM4) contained the fixed 11 
effects of group, time, age, duration of diabetes, HbA1c and the group*time interaction was 12 
fitted. Parameter estimates and corresponding standard errors, P-values and 95% 13 
confidence intervals are given in Table 4. Group and time did not show a significant effect, 14 
while the effects of age at enrolment (β = -0.06, P = 0.04) and duration of diabetes (β = -15 
0.08, P = 0.03) were significant. LMM4 also showed a differential effect of time on the 16 
trajectory of CNFD with the slope decreasing by 0.91 nerve/mm2 for DPN+ve individuals 17 
compared to controls (the reference level of the group). 18 
The examination of significant risk factors for corneal neuropathy in diabetic individuals, 19 
irrespective of the baseline neuropathy status, showed that CNFD was associated with 20 
HbA1c (β = -0.58, P = 0.03) and duration of diabetes (β = -0.08, P = 0.03). CNBD was found to 21 
be affected by the duration of diabetes (β = -0.21, P = 0.01) and smoking (β = -0.25, P = 22 
0.04). No statistically significant association was found between CNFL and the included risk 23 
factors.     24 
Since peroneal nerve conduction velocity was the only measure that showed a significant 25 
worsening in the diabetes group, we sought to compare the trajectories of this parameter 26 
between groups utilizing an additional mixed model (LMM5). The above-mentioned basic 27 
model was repeated with peroneal nerve conduction velocity as the response variable. 28 
There was a significant effect of time (P < 0.01) and group (P < 0.01), but the group*time 29 
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interaction was not significant (P =0.92), indicating that the observed time effect is not 1 
different between groups. 2 
In the diabetic group, bivariate correlation revealed a modest association between absolute 3 
changes of CNBD and peroneal nerve conduction velocity (Pearson r = 0.23, P = 0.02). In the 4 
DPN+ve group, there was a significant correlation between CNBD and peroneal nerve 5 
conduction velocity (Pearson r = 0.38, P = 0.05). The absolute change in CNFL was also 6 
positively correlated to the cold sensation threshold (Pearson r = 0.40, P = 0.03). 7 
Discussion  8 
In vivo assessment of the SNP morphology using CCM has emerged as a valuable clinical 9 
modality to improve our understanding of the relationship between this rich nerve plexus 10 
and various ocular and systemic conditions and diseases. As reviewed in more detail 11 
elsewhere,35, 36 morphometric evaluation of the SNP has been used to diagnose, assess and 12 
follow up ocular surface conditions including ocular allergy, dry eye, infectious keratitis, and 13 
glaucoma and after keratorefractive surgery and contact lens wear. Currently, considerable 14 
evidence exists that advocates the utility of CCM for assessment of small nerve fiber 15 
pathology induced by systemic and neurological conditions, in particular DPN. This study 16 
examined the longitudinal aspect of the utility of CCM to serve as an acceptable measure of 17 
DPN in clinical research and practice.  18 
We report data from a cohort of individuals with type 1 diabetes (n = 147) and healthy 19 
controls (n = 60) collected from baseline to a median duration of 3.7 years. Although the 20 
stability of corneal nerve morphology has been previously demonstrated in a 3-year 21 
longitudinal study in healthy individuals,37 to our knowledge no previous study has 22 
examined the dynamic natural course of SNP microstructures in relation to DPN. With 23 
reference to the lack of previous investigation concerning the natural history of corneal 24 
nerves in diabetes, the present study is a positive response and attempts to fill this research 25 
gap. 26 
At the baseline visit, age was matched between participants with diabetes and controls. 27 
Diabetic participants showed moderate glycemic control and excellent control of 28 
cardiovascular risk factors including the blood pressure and lipid profile in accordance with 29 
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the current treatment guidelines.38 The lower level of total cholesterol and LDL cholesterol 1 
in our diabetic patients as compared to controls is attributed to the fact that 35% were 2 
receiving lipid-lowering medications.  3 
Comparison of the clinical parameters at baseline and final visit showed that there were no 4 
clinically significant changes to health, metabolic and anthropometric measurements, 5 
indicating stable glucose control and desirable maintenance of cardiovascular risk factors. 6 
Although the Hawthorne effect39 may have been involved, the finding of lower alcohol 7 
consumption in the diabetic patients at baseline which is maintained at follow up reflects 8 
good diabetes education. And the significant reduction in tobacco consumption over time in 9 
both diabetic patients and control subjects presumably reflects overall population level of 10 
education to stop smoking.  11 
Except for peroneal nerve conduction velocity, with a statistically significant but clinically 12 
trivial decline (-0.9 m/s), the remaining established measures of neuropathy remained 13 
unchanged or improved slightly from baseline to the final visit. However, LMM5 showed 14 
that changes in peroneal nerve conduction velocity in DPN+ve and DPN-ve patients did not 15 
differ significantly from controls, indicating a similar effect of time for groups. The low rate 16 
of change over time in these measures may be attributed to (a) the maintenance of a 17 
healthy lifestyle and compliance with medical advice among our diabetic cohort; (b) the 18 
inclusion of participants with only mild neuropathy; and (c) the relatively short duration of 19 
study. Negligible worsening or no progression of the traditional measures of DPN has also 20 
been observed in the placebo arm of a recent interventional study40 of 227 patients with 21 
predominantly type 2 diabetes, but with substantially worse glycemic control at baseline 22 
(8.8 + 1.9%) and a reduction of 0.67 + 1.41% over 4 years. Our findings are further 23 
supported by a 3 year longitudinal study of 62 subjects with predominantly type 2 diabetes 24 
and good glycemic control (HbA1c 7.23 + 1.03%), which interestingly demonstrated stability 25 
in a range of neurological examinations, symptom scores, autonomic testing, QST and nerve 26 
conduction studies with worsening only in the sural nerve amplitude and the axon-reflex 27 
vasodilation test, a measure of small fiber neuropathy.41 28 
All three SNP parameters were significantly reduced in diabetic participants without and 29 
with neuropathy at the baseline visit. This finding is consistent with other studies, which 30 
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also show a depletion of SNP tissue in diabetic patients without and with DPN, reflecting 1 
early subclinical small fiber damage.22-24, 42 Based on the reported association of SNP 2 
parameters and DPN severity23, 24 we hypothesised that participants with diabetes and DPN 3 
would demonstrate quicker deterioration of SNP tissue than those without DPN. In order to 4 
examine this hypothesis, we built several linear mixed models. Such models afford robust 5 
methods of analysing longitudinal data with repeated measurements, in particular when the 6 
data is incomplete or unbalanced due to missing data, dropouts or differences in 7 
observation time points.34  8 
According to the three basic mixed models developed here and regardless of group, there 9 
was no significant effect of time for any of the three SNP parameters. A group*time 10 
interaction term was not significant for CNBD or CNFL (P = 0.24 and P = 0.20), indicating that 11 
the presence or absence of DPN at baseline did not appear to impact CNBD and CNFL 12 
changes over time. Mean CNBD (23.7 ± 20.9 vs. 22.7 ± 16.9, no/mm2) and CNFL (15.0 ± 4.3 13 
vs. 14.4 ± 4.1 mm/mm2) declined slightly over 4 years in the neuropathy group, but to an 14 
extent that is neither clinically nor statistically significant.  15 
However, the Type III F test for the interaction between time and group was statistically 16 
significant for CNFD (P = 0.02), suggesting that the relationship of time with CNFD change 17 
varies depending on the group. LMM4 (Table 4) demonstrated that whilst CNFD trajectories 18 
were not statistically different between DPN-ve and controls, the mean CNFD decreased 19 
significantly in the DPN+ve group during follow up, with a loss of approximately 1 20 
nerve/mm2 per year. This observed CNFD change was best predicted by participant age and 21 
duration of diabetes (both P < 0.05). One may anticipate that such a change would be 22 
influenced by glycemic control, however, HbA1c did not reach statistical significance (P = 23 
0.10) in LMM4, where CNFD was considered as a dependent variable, possibly because of 24 
the relative stability of this factor during the study period. Although the outcome of CNFD 25 
decline indicates dynamic structural small nerve fiber damage at the SNP, the relevance of 26 
CNFD change in the neuropathy group and the relative stability of CNBD and CNFL are not 27 
clear. Disparate changes to these three corneal nerve parameters have also been reported 28 
in diabetic individuals after improvement in risk factors for DPN27 and after simultaneous 29 
pancreas and kidney transplantation,43 suggesting a complex, dynamic and perhaps non-30 
linear relationship between these parameters. 31 
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The baseline cross-sectional findings in the present study confirmed that all three SNP 1 
parameters were reduced in the neuropathy group compared to controls. The parameter 2 
that underwent the most marked reduction over time was CNFD. This suggests that branch 3 
damage (thinner branches emanating from major nerves) might represent the primary 4 
pathological change in DPN, whereas CNFD (a parameter related to the major nerve trunks) 5 
deterioration occurs later. The reduction in CNFD along with a non-significant decline of the 6 
other two parameters may also suggest degeneration of major nerve trunks with 7 
concomitant regeneration reflected by an increase in the CNBD and CNFL. Therefore, it is 8 
conceivable that loss and indeed repair of different SNP parameters may occur at different 9 
stages of the disease.  10 
Limited studies are available documenting the link between corneal small nerve fiber 11 
change and risk factors of DPN.21, 27, 44 In the present study, when the data were restricted 12 
to include only diabetic individuals and upon removal of the effect of group in the linear 13 
mixed models, we found that every one-unit increase of HbA1c was associated with a 14 
decrease of ~ 0.6 nerve/mm2 in CNFD. There also was a negative effect of diabetes duration 15 
on CNFD and CNBD. Each 10-year increase of diabetes duration at baseline resulted in 0.8 16 
and 2.0 nerve/mm2 decline of central corneal CNFD and CNBD, respectively. CNBD was also 17 
significantly affected by smoking. Increasing one cigarette per day had a negative effect of 18 
0.25 nerve/mm2.  19 
These results demonstrate the link between risk factors of DPN and morphologic 20 
parameters of corneal nerves. We have no clear explanation why HbA1c has an effect upon 21 
CNFD, but not CNBD and CNFL.  Nevertheless, this finding is in consistent with the study of 22 
Tavakoli et al27 who reported a significant correlation between changes in HbA1c and CNFD 23 
(r = -0.52, P < 0.01) but not for CNBD and CNFL. In a study of 38 type 1 diabetic patients with 24 
and without neuropathy, Ishibashi et al44 reported time-dependent effects of HbA1c on SNP 25 
parameters. While nerve beading frequency was positively correlated to the mean HbA1c 26 
levels at time of, or up to three months prior to CCM examination, no significant association 27 
was found between CNFD and CNFL with HbA1c up to 6 years before CCM examination. 28 
These findings emphasise the importance of including different SNP parameters in future 29 
studies, where these parameters are to be used as measures of small nerve fiber damage 30 
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and in particular repair. Additionally, in this study, only the central cornea has been 1 
investigated. Recent studies have revealed that loss of corneal neve structure in the SNP 2 
mainly occurred at the inferior whorl, which is slightly more distal than the central cornea 3 
and may therefore be expected to show more marked pathology.45, 46 Further longitudinal 4 
work assessing the inferior whorl as opposed to the central cornea may provide additional 5 
insights and ability to discriminate change in relation to DPN. 6 
In previous cross-sectional studies, SNP parameters have been shown to correlate with 7 
functional and structural measures of neuropathy.19, 23, 25 Quattrini et al19 reported a 8 
significant correlation between CNFD versus NDS (r = -0.30, P = 0.03) and cold sensation 9 
threshold (r = -0.40, P < 0.01). In a subsequent study, moderate correlations were found 10 
between NDS and corneal nerve parameters (rs, -0.48 to -0.58; P < 0.001).
23 In a recent study 11 
by Sivaskandarajah et al,25 CNFD, CNBD and CNFL were related to cold sensation threshold 12 
(rs,  0.32 to 0.37; P ≤ 0.01). In this longitudinal study, we examined the relationship of 13 
change in corneal nerve parameter with conventional measures of neuropathy by 14 
calculating the absolute change from baseline to final visit for participants with diabetes. 15 
We found a modest correlation between CNBD and peroneal conduction velocity (Pearson r 16 
= 0.23, P = 0.02). When the data was restricted to the DPN+ve group, this correlation 17 
increased to 0.38. Furthermore, CNFL also correlated to cold sensation threshold (r = 0.40, P 18 
= 0.03), which indicates that SNP parameters do change in a fashion comparable with some 19 
traditional measures of neuropathy. 20 
The key strengths of this study are its longitudinal nature, inclusion of a range of traditional 21 
neuropathy measures (small and large nerve fiber dysfunction) in a relatively large number 22 
of type 1 diabetic participants, the consistency and strict adherence to technical and 23 
methodological procedures such as capturing and selection criteria of the SNP images, and 24 
employing a fully-automated image analysis algorithm, which is essential to eliminate the 25 
variability associated with manual and semi-automated analysis. Thus we used a fully 26 
automated image analysis algorithm which has been validated and compared against the 27 
manual and semi-automated analysis33, 42, 47 in individuals with diabetes.  28 
A limitation of this study is that a majority of type 1 participants were enrolled from 29 
specialized clinics, where the glycemic and cardiovascular factors were optimally controlled, 30 
16 
 
which may not represent the typical population with type 1 diabetes. Additionally, four 1 
years of study might be insufficient to discern changes over time, particularly in the case of 2 
patients with mild neuropathy or the limited number of apparently motivated participants 3 
with well-controlled diabetes available in the neuropathy group.  4 
In conclusion, the findings presented herein provide evidence that CCM has the potential to 5 
track the structural alterations of the small nerve fibers in DPN. Furthermore, these findings 6 
support the notion that quantification of the SNP morphology has a substantial potential to 7 
be employed as an appropriate adjunct measure to conventional measures of DPN.  8 
17 
 
  
  References 
 
1. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of  
diabetic neuropathy, retinopathy and nephropathy in a population-based cohort  - the Rochester 
Diabetic Neuropathy Study. Neurology 1993;43:817-824. 
2. Chin RL, Rubin M. Diabetic Neuropathy. In: Poretsky L (ed), Principles of Diabetes Mellitus: 
Springer US; 2010:357-370. 
3. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic Foot Disorders: A Clinical Practice 
Guideline (2006 Revision). The Journal of Foot and Ankle Surgery 2006;45:S1-S66. 
4. Happich M, John J, Stamenitis S, Clouth J, Polnau D. The quality of life and economic burden 
of neuropathy in diabetic patients in Germany in 2002 - Results from the diabetic microvascular 
complications (DIMICO) study. Diabetes Res Clin Pract 2008;81:223-230. 
5. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of 
peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients 
attending hospital outpatients clinics. Diabetes Metab 2009;35:206-213. 
6. Dyck PJ, Overland CJ, Low PA, et al. Signs and Symptoms vs Nerve Conduction Studies to 
Diagnose Diabetic Sensorimotor Polyneuropathy. Muscle Nerve 2010;42:157. 
7. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes 
Care 2004;27:1458-1486. 
8. Dyck PJ, Argyros B, Russell JW, et al. Multicenter trial of the proficiency of smart quantitative 
sensation tests. Muscle Nerve 2014;49:645-653. 
9. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to 
diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010;42:157-164. 
10. Litchy WJ, Albers JW, Wolfe J, et al. Proficiency of nerve conduction using standard methods 
and reference values (Cl. NPhys Trial 4). Muscle Nerve 2014. 
11. Asghar O, Petropoulos IN, Alam U, et al. Corneal Confocal Microscopy Detects Neuropathy in 
Subjects With Impaired Glucose Tolerance. Diabetes Care 2014. 
12. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal 
microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014;63:2454-2463. 
13. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with 
minimal but progressive neuropathy. Diabetologia 2005;48:578-585. 
18 
 
14. Lauria G, Lombardi R, Camozzi F, Devigili G. Skin biopsy for the diagnosis of peripheral 
neuropathy. Histopathology 2009;54:273-285. 
15. Li C, Bunner AE, Pippin JJ. From animal models to clinical practicality: lessons learned from 
current translational progress of diabetic peripheral neuropathy. In: Souayah N (ed), Peripheral 
Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex 
Disorder: InTech; 2013:29-76. 
16. Varkonyi T, Putz Z, Keresztes K, et al. Current options and perspectives in the treatment of 
diabetic neuropathy. Curr Pharm Des 2013;19:4981-5007. 
17. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical 
manifestations and current treatments. Lancet Neurol 2012;11:521-534. 
18. Malik RA. From the bedside to the bench and back again, with corneal confocal microscopy. 
Invest Ophthalmol Vis Sci 2014;55:1231. 
19. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in 
human diabetic neuropathy. Diabetes 2007;56:2148-2154. 
20. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal microscopy: A non-invasive 
surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003;46:683-688. 
21. Edwards K, Pritchard N, Vagenas D, Russell A, Malik RA, Efron N. Utility of corneal confocal 
microscopy for assessing mild diabetic neuropathy: baseline findings of the LANDMark study. Clin 
Exp Optom 2012;95:348-354. 
22. Ahmed A, Bril V, Orszag A, et al. Detection of diabetic sensorimotor polyneuropathy by 
corneal confocal microscopy in Type 1 diabetes A concurrent validity study. Diabetes Care 
2012;35:821-828. 
23. Tavakoli M, Quattrini C, Abbott C, et al. Corneal confocal microscopy: A novel noninvasive 
test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 
2010;33:1792-1797. 
24. Petropoulos IN, Alam U, Fadavi H, et al. Corneal nerve loss detected with corneal confocal 
microscopy is symmetrical and related to the severity of diabetic polyneuropathy. Diabetes Care 
2013. 
25. Sivaskandarajah GA, Halpern EM, Lovblom LE, et al. Structure-function relationship between 
corneal nerves and conventional small-fiber tests in type 1 diabetes. Diabetes Care 2013. 
26. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, et al. Corneal confocal microscopy detects 
early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney 
transplantation. Diabetes 2013;62:254-260. 
19 
 
27. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in 
corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med 
2011;28:1261-1267. 
28. Pritchard N, Edwards K, Dehghani C, et al. Longitudinal assessment of neuropathy in type 1 
diabetes using novel ophthalmic markers (LANDMark): study design and baseline characteristics. 
Diabetes Res Clin Pract 2014;104:248-256. 
29. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, 
diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285-2293. 
30. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicenter study of the 
prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. 
Diabetologia 1993;36:150-154. 
31. Meijer J, Smit A, Sonderen E, Groothoff J, Eisma W, Links T. Symptom scoring systems to 
diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med 
2002;19:962-965. 
32. Vagenas D, Pritchard N, Edwards K, et al. Optimal image sample size for corneal nerve 
morphometry. Optom Vis Sci 2012;89:812–817. 
33. Dabbah MA, Graham J, Petropoulos IN, Tavakoli M, Malik RA. Automatic analysis of diabetic 
peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal 
microscopy imaging. Med Image Anal 2011;15:738-747. 
34. Shek DT, Ma C. Longitudinal data analyses using linear mixed models in SPSS: concepts, 
procedures and illustrations. The Scientific World Journal 2011;11:42-76. 
35. Villani E, Mantelli F, Nucci P. In-vivo confocal microscopy of the ocular surface: ocular allergy 
and dry eye. Curr Opin Allergy Clin Immunol 2013;13:569-576. 
36. Villani E, Baudouin C, Efron N, et al. In vivo confocal microscopy of the ocular surface: from 
bench to bedside. Curr Eye Res 2013;1-19. 
37. Dehghani C, Pritchard N, Edwards K, et al. Morphometric stability of the corneal subbasal 
nerve plexus in healthy individuals: a 3-year longitudinal study using corneal confocal microscopy. 
Invest Ophthalmol Vis Sci 2014;55:3195-3199. 
38. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 
2014;37:S14-S80. 
39. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: New 
concepts are needed to study research participation effects. J Clin Epidemiol 2014;67:267-277. 
40. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic 
acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34:2054-2060. 
20 
 
41. Gibbons CH, Freeman R, Tecilazich F, et al. The evolving natural history of neurophysiologic 
function in patients with well‐controlled diabetes. J Peripher Nerv Syst 2013;18:153-161. 
42. Petropoulos IN, Alam U, Fadavi H, et al. Rapid automated diagnosis of diabetic peripheral 
neuropathy with in vivo corneal confocal microscopy. Invest Ophthalmol Vis Sci 2014. 
43. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve 
regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 
2007;30:2608-2612. 
44. Ishibashi F, Okino M, Ishibashi M, et al. Corneal nerve fiber pathology in Japanese type 1 
diabetic patients and its correlation with antecedent glycemic control and blood pressure. Journal of 
Diabetes Investigation 2012;3:191-198. 
45. Davidson EP, Coppey LJ, Kardon RH, Yorek MA. Differences and similarities in development 
of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic 
rats. Invest Ophthalmol Vis Sci 2014;55:1222-1230. 
46. Edwards K, Pritchard N, Gosschalk K, et al. Wide-field assessment of the human corneal 
subbasal nerve plexus in diabetic neuropathy using a novel mapping technique. Cornea 
2012;31:1078-1082. 
47. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA, Efron N. Fully automated, 
semiautomated, and manual morphometric analysis of corneal subbasal nerve plexus in individuals 
with and without diabetes. Cornea 2014;33:696-702. 
 
  
21 
 
Tables 
 
Table 1. Demographic and clinical characteristics of the participants at the baseline and final 
visit. Results are expressed as mean ± SD or counts for categorical variable. 
 Baseline Year 4 follow up P-value 
Parameter Control (A) Diabetes (B) Control (C) Diabetes (D) A vs. B A vs. C B vs D 
n (male/female) 60 (26/34) 147 (71/76) 51 (22/29) 133 (67/66) 0.52* 0.98* 0.73* 
Age (years) 51.0 ± 14.7 47.3 ± 15.4 57.0 ± 13.7 52.0 ± 15.3 0.11† - - 
Duration of 
diabetes (years) 
0 19.8 ± 14.5 0 24.0 ± 14.8 - - - 
HbA1c (%) 5.4 ± 0.3 8.1 ± 1.4 5.2 ± 0.5 8.0 ± 1.5 < 0.001‡ < 0.001§ 0.65# 
Total cholesterol 
(mmol/L) 
5.4 ± 1.2 4.7 ± 0.9 5.5 ± 1.1 4.6 ± 0.9 < 0.001† 0.83§ 0.23§ 
HDL (mmol/L) 1.5 ± 0.4 1.6 ± 0.4 1.4 ± 0.3 1.5 ± 0.4 0.26‡ 0.06§ 0.78# 
LDL (mmol/L) 3.5 ± 1.1 2.7 ± 0.8 3.5 ± 1.1 2.5 ± 0.7 < 0.001† 0.96§ 0.07§ 
Triglycerides 
(mmol/L) 
1.1 ± 0.6 1.1 ± 0.6 1.2 ± 0.5 1.1 ± 0.8 0.43‡ 0.27§ 0.40# 
Systolic BP 
(mmHg) 
116.1 ± 
13.6 
121.0 ± 16.5 117.1 ± 13.7 118.8 ± 12.1 0.03§ 0.88§ 0.12§ 
Diastolic BP 
(mmHg)  
72.8 ± 7.0 72.7 ± 8.6 71.7 ± 8.2 71.2 ± 7.0 0.89† 0.27§ 0.13§ 
BMI (kg/m2) 26.1 ± 5.2 26.5 ± 4.4 26.8 ± 4.9 26.9 ± 4.7 0.46† 0.42§ 0.02§ 
Alcohol 
consumption 
(units/week) 
5.0 ± 5.7 1.9 ± 1.8 5.2 ± 6.1 1.8 ± 1.8 0.001‡ 0.78# 0.20# 
Cigarettes 
smoked 
(number/day) 
6.7 ± 11.5 5.1 ± 8.0 1.3 ± 5.2 1.3 ± 5.6 0.74‡ < 0.001# < 0.001# 
*Chi square test, †Independent samples test, ‡ Mann-Whitney test, § paired samples t test, #Wilcoxon test 
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Table 2. Baseline comparison of corneal nerve parameters and neuropathy measures in the 
study participants according to presence and absence of neuropathy defined by Toronto 
criteria. Outcomes are presented as mean ± SD. 
  DPN status at baseline  
Characteristics Controls 
n = 60 
DPN-ve 
n =108 
DPN+ve 
n =39 
P 
Group difference 
Corneal nerve parameters 
CNFD 
(number/mm2) 
22.3 ± 8.0 18.3 ± 7.1 16.3 ± 8.3 < 0.001* 
Controls vs. DPN-ve, DPN+ve† 
CNBD 
(number/mm2) 
35.1 ± 23.8 24.2 ± 17.4 23.7 ± 20.9 0.003‡ 
Controls vs. DPN-ve, DPN+ve§ 
CNFL (mm/mm2) 18.1 ± 3.7 16.0 ± 3.8 15.0 ± 4.3 < 0.001* 
Controls vs. DPN-ve, DPN+ve†  
Quantitative Sensory Tests 
Cold sensation 
threshold (°C) 
28.4 ± 2.8 27.4 ± 5.1 23.4 ± 7.2 < 0.001‡ 
Controls vs. DPN+ve§ 
DPN-ve vs. DPN+ve§ 
Warm sensation 
threshold (°C) 
38.0 ± 4.1 37.4 ± 3.8 41.6 ± 3.7 < 0.001‡ 
Controls vs. DPN+ve§ 
DPN-ve vs. DPN+ve§ 
Vibration threshold 
(Hz) 
7.0 ± 8.1  8.7 ± 10.3 25.7 ± 22.2 < 0.001‡ 
Controls vs. DPN+ve§ 
DPN-ve vs. DPN+ve§ 
Nerve Conduction Studies 
Peroneal F latency 
(ms)  
49.6 ± 5.2 51.5 ± 4.9 55.7 ± 5.0 < 0.001* 
Controls vs. DPN+ve†  
DPN-ve. vs DPN+ve† 
Peroneal nerve 
amplitude (mV) 
4.7 ± 2.3 5.2 ± 2.7 2.7 ± 1.8 < 0.001‡ 
Controls vs. DPN+ve§ 
DPN-ve vs. DPN+ve§ 
Peroneal nerve 
conduction velocity 
(m/s) 
49.0 ± 5.5 46.7 ± 5.0 39.6 ± 5.9 < 0.001* 
Controls vs. DPN-ve, DPN+ve†  
DPN-ve vs. DPN+ve†  
Neuropathy disability 
score (0–10) 
0.4 ± 0.9 0.6 ± 0.9 2.2 ± 1.5 < 0.001‡ 
Controls vs. DPN+ve§ 
DPN-ve vs. DPN+ve§ 
Diabetic neuropathy 
symptom score (0–4) 
0.1 ± 0.3 0.2 ± 0.5 1.1 ± 1.0 < 0.001‡ 
Controls vs. DPN+ve§ 
DPN-ve vs. DPN+ve§ 
DPN-ve, diabetic participant without neuropathy; DPN+ve, diabetic participant with neuropathy 
* One way ANOVA test, † Scheffe post hoc test, ‡ Kruskal Wallis test, § Mann-Whitney test 
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Table 3. Results of Type III tests of fixed effects from the three initial linear mixed models 
analysis. Dependent variables were CNFD in linear mixed model 1 (LMM1), CNBD in LMM2, 
and CNFL in LMM3. 
 LMM1 LMM2 LMM3 
 F P F P F P 
Intercept 1420.0 < 0.001 423.2 < 0.001 4254.4 < 0.001 
Group 8.2 < 0.001 7.4 0.001 10.9 < 0.001 
Time (years) 0.03 0.87 1.8 0.18 0.5 0.49 
Group*Time 4.0 0.02 1.4 0.24 1.6 0.20 
 
 
 
 
Table 4. Maximum likelihood of the fixed effect parameters for linear mixed model 4, with 
CNFD as the continuous response variable. 
Parameter Estimate (95% CI) Std. Error P-value 
Intercept 27.57 (23.01-32.12) 2.32 < 0.001 
Time (years) 0.35 (-0.10-0.80) 0.23 0.13 
Group 
DPN+ve -1.36 (-5.17-2.45) 1.94 0.48 
DPN-ve -1.33 (-4.18-1.52) 1.45 0.36 
Controls 0* 0 . 
Age at enrolment (years) -0.06 (-0.12-0.00) 0.03 0.04 
Duration of Diabetes (years) -0.08 (-0.16 to -
0.01) 
0.04 0.03 
HbA1C (%) -0.41 (-0.89-0.08) 0.25 0.10 
Group*Time 
DPN+ve * Time -0.91 (-1.63 to -
0.20) 
0.37 0.01 
DPN-ve * Time -0.26 (-0.82-0.31) 0.30 0.37 
Controls * Time 0* 0 . 
* This parameter is set to zero because it is the reference level of the 
group. 
 
  
24 
 
 
Figure Legends 
 
Figure 1. Distribution and number of participants examined at various time points. DPN-ve, 
diabetic participant without neuropathy; DPN+ve, diabetic participant with neuropathy 
 
Figure 2. Longitudinal course of corneal nerve fiber density (A), branch density (B) and fiber 
length (C) over time. On each graph, the solid line represents control participants, the 
dashed line represents diabetic participant without neuropathy and the dotted line 
represents diabetic participant with neuropathy. Error bars indicate mean ± SEM. 


